Adjuvant endocrine therapy for perimenopausal women with early breast cancer

被引：11

作者：

Ortmann, Olaf ^{[1
]}

Cufer, Tanja ^{[2
]}

Dixon, J. Michael ^{[3
]}

Maass, Nicolai ^{[4
]}

Marchetti, Paolo ^{[5
]}

Pagani, Olivia ^{[6
]}

Pronzato, Paolo ^{[7
]}

Semiglazov, Vladimir ^{[8
]}

Spano, Jean-Philippe ^{[9
]}

Vrdoljak, Eduard ^{[10
]}

Wildiers, Hans ^{[11
]}

机构：

[1] Univ Regensburg, Dept Obstet & Gynecol, Caritas Hosp St Josef, D-93053 Regensburg, Germany

[2] Inst Oncol, Ljubljana, Slovenia

[3] Western Gen Hosp, Edinburgh Breast Unit, Edinburgh EH4 2XU, Midlothian, Scotland

[4] Univ Kiel, Kiel, Germany

[5] Osped Sant Andrea, Dept Med Oncol, Rome, Italy

[6] Inst Oncol So Switzerland, Bellinzona, Switzerland

[7] Inst Nazionale Ricerca Cancro, Genoa, Italy

[8] Petrov Res Inst Oncol, St Petersburg, Russia

[9] Grp Hosp Pitie Salpetriere, Dept Med Oncol, F-75634 Paris, France

[10] Univ Split, Ctr Oncol, Sch Med, Clin Hosp Split, Split, Croatia

[11] Multidisciplinary Breast Ctr, Dept Gen Med Oncol, Louvain, Belgium

来源：

BREAST | 2009年 / 18卷 / 01期

关键词：

Adjuvant; Perimenopausal; Breast carcinoma; Endocrine therapy; Ovarian function suppression; PREMENOPAUSAL WOMEN; POSTMENOPAUSAL WOMEN; AROMATASE INHIBITORS; RANDOMIZED-TRIAL; MENOPAUSAL TRANSITION; OVARIAN-FUNCTION; YOUNG-WOMEN; TAMOXIFEN; HORMONE; CHEMOTHERAPY;

D O I：

10.1016/j.breast.2008.10.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Adjuvant treatment with aromatase inhibitors (AIs) improves outcomes in postmenopausal women with hormone-sensitive early breast cancer compared with tamoxifen However AIs should not be used in., premenopausal women because they can paradoxically increase estrogen secretion and may therefore stimulate tumor progression. In perimenopausal women undergoing treatment for breast cancer, it can be difficult to determine true menopausal Status because adjuvant chemotherapy, tamoxifen, and gonadotropin-releasing hormone analogues can induce transient (or permanent) ovarian suppression. How can one determine whether these women are truly postmenopausal and therefore candidates for AI therapy? A panel of experts in the field of endocrine therapy in breast cancer met in Dubrovnik, Croatia, on October 23, 2006, to discuss this clinical dilemma. This report summarizes the conclusions and recommendations that arose from this discussion. (C) 2008 Published by Elsevier Ltd.

引用

页码：2 / 7

页数：6

共 37 条

[1] The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer [J].

Anderson, R. A. ;

Themmen, A. P. N. ;

Al-Qahtani, A. ;

Groome, N. P. ;

Cameron, D. A. .

HUMAN REPRODUCTION, 2006, 21 (10) :2583-2592

[2]

[Anonymous], NCCN CLIN PRACT GUID

[3]

Baum M, 2002, LANCET, V359, P2131

[4] Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole trial [J].

Boccardo, F ;

Rubagotti, A ;

Puntoni, M ;

Guglielmini, P ;

Amoroso, D ;

Fini, A ;

Paladini, G ;

Mesiti, M ;

Romeo, D ;

Rinaldini, M ;

Scali, S ;

Porpiglia, M ;

Benedetto, C ;

Restuccia, N ;

Buzzi, F ;

Franchi, R ;

Massidda, B ;

Distante, V ;

Amadori, D ;

Sismondi, P .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (22) :5138-5147

[5] Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: Cases and lessons [J].

Burstein, Harold J. ;

Mayer, Erica ;

Partridge, Ann H. ;

O'Kane, Holly ;

Litsas, Georgia ;

Come, Steven E. ;

Hudis, Clifford A. ;

Goldstein, Donald F. ;

Muss, Hyman B. ;

Winer, Eric P. ;

Garber, Judy E. .

CLINICAL BREAST CANCER, 2006, 7 (02) :158-161

[6]

Carlson RW, 2004, BREAST CANCER RES TR, V88, pS237

[7]

Carrizosa Daniel R, 2005, Breast Dis, V23, P67

[8]

Celio L, 1999, ANTICANCER RES, V19, P2261

[9] Identifying menopause in breast cancer patients: considerations and implications [J].

Clemons, Mark ;

Simmons, Christine .

BREAST CANCER RESEARCH AND TREATMENT, 2007, 104 (02) :115-120

[10] A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer [J].

Coombes, RC ;

Hall, E ;

Gibson, LJ ;

Paridaens, R ;

Jassem, J ;

Delozier, T ;

Jones, SE ;

Alvarez, I ;

Bertelli, G ;

Ortmann, O ;

Coates, AS ;

Bajetta, E ;

Dodwell, D ;

Coleman, RE ;

Fallowfield, LJ ;

Mickiewicz, E ;

Andersen, J ;

Lonning, PE ;

Cocconi, G ;

Stewart, A ;

Stuart, N ;

Snowdon, CF ;

Carpentieri, M ;

Massimini, G ;

Bliss, JM .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (11) :1081-1092

← 1 2 3 4 →